Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REOLYSIN with Paclitaxel and Carboplatin in Squamous Cell Lung Cancer
NCT00998192Phase 2Completed
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Oct 2009
- Primary completion
- Sep 2013
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pelareorep in lung squamous cell carcinoma (LSCC), sponsored by Oncolytics Biotech Inc. Primary endpoint: Objective Response Rate at 6 months. Started Oct 2009; status: completed.
02
Drugs
pelareorep
03
Conditions
lung squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT00998192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998192.